Leukopaks are highly concentrated, low-volume apheresis collections that contain large numbers of mononuclear cells (MNCs). As an essential source of primary immune cells for drug development research, leukopaks are an ideal starting material for downstream cell isolation when large numbers of cells are required. This webinar highlights insights and techniques for efficient leukopak sample processing to reduce the time and reagents required to process cells of interest.

Do you:
• Wish you could get HEOR, RWE and Market Access projects started faster, cheaper, & using the most optimal solution provider?
• Get frustrated with slow contracting?
• Want better and more targeted ways to find suppliers and databases that meet your research needs?

Attend this on-camera webinar, panel discussion and demonstration of the HEOR & RWE Marketplace, the pharma industry’s largest online marketplace for outsourced research.

The webinar will be presented by Marketplace partners HealthEconomics.Com & Scientist.com.

The novel SubQperior tumor models overcome common challenges of subcutaneous tumor models based on improved tumor cell implantation technique. SubQperior efficacy studies provide outstanding statistical value due to homogenous tumor growth and absence of ulceration issues. In this webinar, we present how SubQperior syngeneic models are used at Reaction Biology to advance immune-oncology drug development programs to create efficacious immunotherapies. All oncology program leaders are welcome to take part in the webinar.

Advancing your drug or vaccine candidate from late-stage discovery into the clinic is one of the most critical steps in development. This is the phase when you make key decisions that will have long-term scientific and business impact, frequently under extreme time and cost pressure. For example, developability and manufacturability issues can arise due to post-translational modifications and aggregation, and immunogenicity risks due to the presence of T-cell epitopes.

Local legislation surrounding the sourcing of human biosamples for research purposes varies greatly around the world. In this webinar we will explore and better understand how India governs the recruitment, collection, storage and distribution (import/export) of human biological samples (HBS) for research.

Choosing the right disease model for preclinical studies is not an easy task, especially with so many options available. Scientist.com has built a Disease Model Finder to address the challenges facing researchers looking to source patient-derived xenograft (PDX) and other disease models. Join our discussion as we bring together research scientists and suppliers of disease models to address this issue.

In this one-hour webinar, experts from Scientist.com and RockStep Solutions will discuss the digitalization of sample collection for dynamic in vivo studies. They will cover common challenges for researchers, technicians, and study monitors tasked with maintaining high-quality non-GLP study conduct in a fast-paced environment. Afterwards, they will present digital solutions and their application in real-world situations. A question and answer session will follow.

Discovery Life Sciences has developed a new bundled solution leveraging Illumina’s TruSight Oncology 500 (TSO00) Solid Tumor (FFPE) and cfDNA that delivers actionable, reliable NGS data across matched FFPE tumor and plasma biospecimens. These biomarkers can have relevance for disease detection, disease progression and relapse over time, and can indicate potential response to treatment for use in the discovery, development and validation of liquid biopsy tests and targeted oncology therapies.

To support the drug discovery community with the challenge to identify efficacious COVID-19 drugs, we have developed specific assays to block SARS-CoV-2 virus entry and replication. In this presentation we looked at biochemical protease assays we have in our COVID panel, including host proteases which enable viral entry (TMPRSS2, Furin, and Cathepsin L), as well as viral proteins involved in viral polyprotein processing (PLpro and Mpro). Next, we discussed our SPR assays for targeting viral entry by testing molecules that can block the interaction between the viral Spike protein (specially looking at the receptor binding domain in this work) and the host protein ACE2.

To address the challenges biobanks face during human biological sample provision, Scientist.com partnered with the UKCRC Tissue Directory and Coordination Centre (TDCC) to host a 3-part webinar series. Although the focus was on UK-based biobanks, the discussions and outcomes are globally applicable to any provider of human biological samples or research organization looking to procure human samples for scientific research. Find a debrief with summaries and videos of all three events below.

In mid-August, the Bio-Techne team shared their vast industry expertise in a webinar focusing on recombinant protein selection, customization and application. The featured panelists—Bio-Techne’s Martin Ramsden, Director Commercial Development and John Humphrey, Director Molecular and Cellular Biology—presented on recombinant protein applications, specifically biotinylated proteins, including site-specific Avi-tag biotinylation. Humphrey also spoke at length about COVID-19 SARS proteins available through Bio-Techne.

Wish you could get HEOR & RWE projects started faster, cheaper, & using the most optimal vendor? Do you want to connect with new buyers in this age of reduced face-to-face business development?

This on-demand webinar features speakers on-camera for greater interactivity & include a demonstration of the newly enhanced HEOR & RWE Marketplace, the pharma industry’s largest online marketplace for outsourced research. The webinar is presented by Marketplace partners HealthEconomics.Com & Scientist.com.

Meaghan Loy, MS, ALAT, SOT Associate Member and Category Director of In Vivo Services at Scientist.com hosted the  3-part webinar series that focused on animal welfare within scientific research. We collaborated with the UK’s National Centre for the Replacement, Refinement & Reduction of Animals in Research (NC3Rs) to co-host the series and had guests from  Mimetas, Hera Biolabs, and Sinclair Research to offer their technologies and solutions. Each webinar in the three-part educational series focused on the 3Rs of Animals in Research—Replacement, Reduction and Refinement—which are key factors in improving animal welfare in all types of research. Replacing animals with in vitro or in silico methods, reducing the numbers of animals used and refining procedures to reduce pain and distress are all critical to overall welfare. The 3Rs help us fulfill our moral and ethical obligations to the animals that have allowed many of the most important modern medical advances to occur. As straightforward as the 3Rs may sound, they can present a unique set of challenges upon implementation. It’s easy to continue conducting the same tried and true studies, but there are many recent innovations that researchers may not be aware of.

Sponsored by IQVIA

Panelists: Nancy A. Dreyer, MPH, PhD, FISPE, Senior VP and CSO for Real World Solutions at IQVIA

Matthew W. Reynolds, PhD, FISPE, VP, Real World Evidence, IQVIA

IQVIA experts will provide a detailed look into various types of real world data (RWD) sources and how they are being used to strengthen insights about COVID-19, including its effects on people who are infected but not hospitalized.

Learn about IQVIA’s COVID Active Research Experience (CARE) Project, as well as approaches to utilizing and the benefits of person-generated health data, and how that data can be strengthened by linkage with secondary data. The session will examine key attributes of the data, strengths, limitations, and uses for addressing questions of interest to patients, care providers, health systems, and payers, as well as other key stakeholders.

Join Health Economics.Com and Syapse as their experts share how to establish high quality, real-world datasets by using a multi-source strategy. A single source of data is often not enough to generate meaningful real-world evidence. Have you recently made an investment in a large raw real-world dataset, and are now drowning in data but lacking in evidence? During this webinar, they will highlight strategic approaches you, and your organization, should consider as you invest in RWD to best capture the comprehensive patient journey needed to answer your most challenging questions, or seek to validate real-world endpoints.

This Masterclass mini-series is led by Stuart Pocock, Professor of Medical Statistics at the London School of Hygiene and Tropical Medicine (>500 (+70 NEJM/Lancet) papers, extensive experience of EMA/FDA and data monitoring committees, including the adaptive, platform, Covid-19 DISCOVERY trial) and chaired by Nawab Qizilbash, Senior Epidemiologist/Clinician at OXON and Hon. Associate Professor, London School of Hygiene and Tropical Medicine and Former Hon. Consultant Physician, Radcliffe Hospitals, Oxford.

It includes 4 free live masterclass sessions to learn about perspectives on real-world evidence explained in clear non-technical terms and illustrated with examples from drugs and devices in multiple therapy areas. Attendees will learn about the role and pros and cons of Real-World Data studies compared with trials and receive guidance to overcome challenges in future RWE studies.